Previous topic
References

Basic Pharmacokinetics Bibliography
  1. Aronoff George R, et al: Drug Prescribing in Renal Failure. Philadelphia, PA. ACP, 1999.
  2. Bauer, Larry A. Applied Clinical Pharmacokinetics. McGraw-Hill. 2001.
  3. Evans W, Schentag J, Jusko J (eds): Applied Pharmacokinetics 3rd edition. San Francisco, CA. Applied Therapeutics, 1992.
  4. Murphy John E (Editor): Clinical Pharmacokinetics 2nd edition. Bethesda, MD. ASHP, 2001.
  5. Ritschel WA: Handbook of Basic Pharmacokinetics, 5th edition. Washington, DC. APhA, 1999.
  6. DiPiro JT, Blouid RA, Pruemer JM. Concepts in Clinical Pharmacokinetics. Bethesda, MD. ASHP, 1988.
  7. Caviness MD, MacKichan J, et al. Therapeutic Drug Monitoring: A guide to clinical application. Irving, TX. Abbott Labs, 1987.
  8. Winter, Michael: Basic Clinical Pharmacokinetics 4th Edition. Philadelphia, PA. Lippincott, 2004.


Creatinine Clearance Bibliography

  1. Clinical Practice Guidelines for Estimation of GFR. National Kidney Foundation, 2002.
  2. Lott RS, Hayton WL: Estimation of Creatinine Clearance from Serum Creatinine Concentration - a review. DICP. 1978;12:140-150.
  3. Hull JH, et al. Influence of range of renal function and liver disease on predictability of creatinine clearance. Clin Pharmacol Ther 1981;30:414-21.
  4. Sawyer WT, et al, Variables Affecting Creatinine Clearance Prediction. Am J Hosp Pharm 1983;40:2175-80.
  5. Canaday BR, et al, Fractional Adjustment of Predicted Creatinine Clearance in Females. Am J Hosp Pharm 1984;41:1842-3.
  6. Chow MS, Schweizer R, Estimation of Creatinine Clearance in Patients with Unstable Serum Creatinine Concentrations: Comparison of Multiple Methods. DICP. 1985;19:385-390.
  7. Bennett WM. Drug Therapy in Renal Disease. In: Scientific American Medicine. New York: Scientific American Inc., 1986: 10(II):A1-27.
  8. Mayersohn M. Special Pharmacokinetic Considerations in the Elderly. In: Applied Pharmacokinetics, 2nd Edition. Spokane, WA: Applied Therapeutics, Inc., 1986. pp 229-293.
  9. Gibson TP. Influence of Renal Disease on Pharmacokinetics. In: Applied Pharmacokinetics, 2nd Edition. Spokane, WA: Applied Therapeutics, Inc., 1986. pp 83-115.
  10. Rhodes PJ, et al: Evaluation of Eight Methods for Estimating Creatinine Clearance in Men. Clin Pharm. 1987;6:399-406.
  11. Caldwell JR. Alterations in Renal Function in the Elderly Population: Implications for Medication Prescribing. Cons Pharm. 1987;Supp B:3-7.
  12. Lipman AG. Drug Therapy Considerations in the Renally Compromised Geriatric Patient. Cons Pharm. 1987;Supp B:3-7.
  13. Melamed AJ, Vanamee P. Estimating creatinine clearance in patients with cancer. Hosp Pharm 1988;23:898-901.
  14. Drusano GL, et al. Commonly used methods of estimating creatinine clearance are inadequate for elderly debilitated nursing home patients. JAGS 1988;36:437-441.
  15. Lau AH, et al. Estimation of creatinine clearance in malnourished patients. Clin Pharm 1988:7;62-65.


Aminoglycoside Bibliography

  1. Devine B, Gentamicin therapy. DICP 1974;8:650-655.
  2. Sarubbi FA, Hull JW. Gentamicin serum concentrations: pharmacokinetic predicitions. Ann Intern Med 1976;85:183-189.
  3. Sawchuk RJ, Zaske DE, et al. Kinetic model for gentamicin dosing. Clin Pharmacol Ther 1977;21;3:362-369.
  4. Sarubbi FA, Hull JW. Amikacin serum concentrations: predicition of levels and dosage guidelines. Ann Intern Med 1978;89:612-618.
  5. Nicolau DP, et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemo 1995;29;3:650-655.
  6. Blouin RA, et al. Tobramycin pharmacokinetics in morbidly obese patients. Clin Pharmacol Ther 1979;26:508-513.
  7. Bauer LA, et al. Amikacin pharmacokinetics in morbidly obese patients. Am J Hosp Pharmacy 1980;37:519-522.
  8. Korsager S. Administration of gentamicin to obese patients. Int J Clin Pharmacol Ther Tox 1980;18,12:549-553.
  9. Lesar TS, et al. Gentamicin dosing errors with four commonly used nomograms. JAMA 1982;248(10);1190-1193.
  10. Sheiner LB, Beal S. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. J Pharm Sci 1982 71:1344-1348.
  11. Matzke GR, Burkle WS, Lucarotti RL. Gentamicin and tobramycin dosing guidelines: an evaluation. DICP 1983;17:425-432.
  12. Yamaoka K, Nakagawa T, et al. A nonlinear multiple regression program based on Bayesian algorithm for microcomputers. J. Pharmacobio-Dyn., 8, 246-256 1985.
  13. Burton ME, Brater DC, et al. A Bayesian feedback method of aminoglycoside dosing. Clin Pharmacol Ther 37:349-357, 1985.
  14. Burton ME, Chow MSS, et al. Accuracy of Bayesian and Sawchuk-Zaske dosing methods for gentamicin. Clin Pharm 1986;5:143-149.
  15. Zaske DE. "Aminoglycosides", in Evans W, Schentag J, Jusko J (eds): Applied Pharmacokinetics. San Francisco. Applied Therapeutics, 1986; pp 331-381.
  16. Schentag JJ, "Aminoglycosides", in Evans W, Schentag J, Jusko J (eds): Applied Pharmacokinetics. San Francisco. Applied Therapeutics, 1986; pp 382-398.
  17. Fant WK. Controversies in antimicrobial therapy: Pitfalls in monitoring aminoglycoside therapy. AJHP 1986:43:641-645.
  18. Chrystyn H. Validation of the use of Bayesian analysis in the optimization of gentamicin therapy. DICP 1988 22:49-53.
  19. Donahue T, Yates DJ. Predictability of aminoglycoside serum levels dosed by a pharmacy protocol. Hospital Pharmacy 1988:23;11-25
  20. Rodvelt KA, Zokufa H, Rotschafer JC. Aminoglycoside pharmacokinetic monitoring: An integral part of patient care? Clin Pharm 1988:7:608-613.
  21. Okamoto MP, Chi A, et al. Comparison of two microcoputer Bayesian pharmacokinetic programs for predicting serum gentamicin concentrations. Clin Pharm 1990 9:708-11.
  22. Tsubaki T, Chandler MHH. Evaluating new and traditional methods for aminoglycoside dosing with various degrees of renal function. Pharmacotherapy 1994; 14:330-336.
  23. Anaizi N. Once-daily dosing of aminoglycosides. A consensus document. Int J Clin Pharmacol Ther. 1997 Jun;35(6):223-6.
  24. Urban AW, Craig WA. Daily dosage of Aminoglycosides. Current Clinical Topics in Infectious Diseases Vol 17, JS Remington & MN Swartz, Eds. Blackwell Science, Malden, MA, 1997.
  25. Demczar DJ, Nafziger AN, Bertino JS. Pharmacokinetics of Gentamicin at Traditional versus High Doses: Implications for Once-Daily Aminoglycoside Dosing. Antimicrob Agents Chemother. 1997 41:1115-1119.
  26. Casano RA, Johnson DF, Bykhovskaya Y, Torricelli F, Bigozzi M, Fischel-Ghodsian N. Inherited susceptibility to aminoglycoside ototoxicity: genetic heterogeneity and clinical implications. Am J Otolaryngol. 1999 May-Jun;20(3):151-6. [ PubMed ]
  27. Hain, TC. Bilateral vestibulopathy. July 2007.


Vancomycin Bibliography

  1. Sheiner LB, Beal S. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. J Pharm Sci 1982 71:1344-1348.
  2. Matzke GR, Kovarik JM, et al. Evaluation of the vancomycin-clearance: creatinine-clearance relationship for predicting vancomycin dosage. Clin Pharm 1985;4:311-315.
  3. Lake KS, Peterson CD. A simplified dosing method for initiating vancomycin therapy. Pharmacotherapy 1985; 5:340-344.
  4. Yamaoka K, Nakagawa T, et al. A nonlinear multiple regression program based on Bayesian algorithm for microcomputers. J. Pharmacobio-Dyn., 8, 246-256 1985.
  5. Rybak MJ, Boike SC. Monitoring vancomycin therapy. DICP 1986;20:757-761.
  6. Matzke GR, Zhanel GG, Guay DRP. Clinical pharmacokinetics of vancomycin. Clin Pharmaco 1986;11:257-282.
  7. Rybak MJ, Boike SC. Individualized adjustment of vancomycin dosage: comparison with two dosage nomograms. DICP 1986;20:64-68.
  8. Cheung RP, DiPiro JT. Vancomycin: An Update. Pharmacotherapy 1986;6:153-69.
  9. Matzke GR. "Vancomycin" In: Applied Pharmacokinetics, Second Edition. Spokane, WA: Applied Therapeutics, Inc., 1986. pp 399-436.
  10. Musa DM, Pauly DJ. Evaluation of a new vancomycin dosing method. Pharmacotherapy 1987;7:69-72.
  11. Garrelts JC, Godley PJ, et al. Accuracy of Bayesian, Sawchuk-Zaske, and nomogram dosing methods for vancomycin. Clin Pharm 1987;6:795-799.
  12. Rodvold KA, et al. Routine monitoring of serum vancomycin concentrations: can waiting be justified? Clin Pharm 1987;6:655-658.
  13. Pyrka RD, Rodvold KA, et al. Individualizing vancomycin dosage regimens: one- versus two-compartment Bayesian models. Ther Drug Mon 1989 11:45-454.
  14. Ackerman, Bruce H. Evaluation of three methods for determining initial vancomycin doses. DICP 1989;23:123-7.
  15. Healy DP, et al. Vancomycin-induced histamine release and 'red man syndrome' comparison of 1- and 2-hour infusions. Antimicrobial Agents and Chemo 34; 550-554, 1990.
  16. Pryka RD, Rovold KA, Erdman SM. An updated comparison of drug dosing methods part IV:vancomycin. Clin Pharmaco 1991;20:463-76.
  17. Ito M, Duren L, et al. Computer program for the initiation of vancomycin therapy. Clin Pharm 1993 12:126-30.
  18. Leader WG, Chandler MH, and Castiglia M. Pharmacokinetic optimisation of Vancomycin therapy. Clin Pharmacokinet 28(4);327-42 1995.
  19. Pou L, Rosell M, et al. Changes in vancomycin pharmacokinetics during treatment. Ther Drug Mon 1996 18:149-153.

Previous topic
References

This page was last modified on January 19 2009

www.rxkinetics.com
©Copyright 1984 - 2018, All rights reserved.
RxKinetics, Plattsburg, MO 64477

This is a Norton safe site

No ads